APIM Therapeutics announced today the publication of research data of ATX-101 in glioblastoma preclinical models in the peer reviewed journal Cancers. The study, conducted in a panel of human glioblastoma and patient-derived glioma-initiating cells, showed that ATX-101 has anticancer activity as a single agent in vitro and in vivo. Furthermore, it potentiated the effect of Radiotherapy in both subcutaneous and intracranial xenograft tumor models. For a copy of the corresponding press release, please follow this link.
